VEGFA and neoplasm: The key points of this study are “focusing on tumor blood vessels consisting of TDECs differentiated from GSCs as one of the causes of resistance to anti‐VEGF pathway inhibitors” and “developing novel angiogenesis inhibitors for TDECs by repositioning existing drugs in the BBB passage”.